ABSIMEDIUM SIGNALFINANCIAL10-K

ABSI shows deteriorating cash burn with operating cash flow worsening to -$92.9M while cash reserves declined substantially to $20.0M, creating near-term funding pressure.

The company's cash position dropped by half to $20.0M while operating losses deepened, creating an urgent need for additional capital given the current burn rate. The expanded share count from 127M to 153M shares suggests recent equity financing, but the proceeds appear insufficient to address the accelerating cash consumption from increased R&D spending.

Comparing 2026-03-24 vs 2025-03-18View on EDGAR →
FINANCIAL ANALYSIS

ABSI's financial position weakened notably as cash reserves fell substantially to $20.0M while operating cash flow deteriorated to -$92.9M from -$72.4M in the prior year. R&D expenses grew meaningfully to $81.4M, reflecting increased investment in drug development programs, though revenue declined modestly to $4.5M. The company reduced total debt by roughly half to $4.0M, but the combination of higher burn rate and lower cash balance creates pressing liquidity concerns despite modest growth in current assets.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-51.4%
$41.2M→$20.0M

Cash declined 51.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Debt
Balance Sheet
-49.6%
$7.9M→$4.0M

Debt reduced 49.6% — deleveraging strengthens balance sheet and reduces financial risk.

Operating Cash Flow
Cash Flow
-28.3%
-$72.4M→-$92.9M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

R&D Expense
P&L
+27.5%
$63.9M→$81.4M

R&D investment increased 27.5% — signals commitment to future product development, though near-term margin impact.

Total Liabilities
Balance Sheet
-22.1%
$34.5M→$26.8M

Liabilities reduced 22.1% — deleveraging improves balance sheet strength and financial flexibility.

Revenue
P&L
-20.7%
$5.7M→$4.5M

Revenue softened 20.7% — monitor whether this is cyclical or structural.

Current Liabilities
Balance Sheet
-20.6%
$28.7M→$22.8M

Current liabilities reduced — improved short-term financial position and working capital health.

Current Assets
Balance Sheet
+11.8%
$133.8M→$149.6M

Current assets grew 11.8% — improving short-term liquidity or inventory/receivables build.

Net Income
P&L
-11.7%
-$103.1M→-$115.2M

Net income declined 11.7% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-10.5%
-$108.9M→-$120.3M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

LANGUAGE CHANGES
NEW — 2026-03-24
PRIOR — 2025-03-18
ADDED
The registrant had outstanding 153,021,263 shares of $0.0001 par value common stock as of March 6, 2026.
Our plans and expectations regarding the initiation, timing, progress, results, and costs of both of our internally developed programs and partnered programs, including current and future preclinical studies and clinical trials, and the period during which the results of such studies and trials will become available, are subject to a high degree of uncertainty.
Our short operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
We will need to raise additional capital to fund our operations, pre-clinical and clinical development of our internally developed programs, and to improve our Integrated Drug Creation platform.
If we are unable to raise additional capital on terms acceptable to us or at all, we may not be able to continue to develop our internally developed programs and/or compete successfully with our Integrated Drug Creation platform, which would harm our business, operations, and financial condition.
+7 more — sign up free →
REMOVED
The registrant had outstanding 127,333,887 shares of $0.0001 par value common stock as of February 28, 2025.
Our current business has a limited operating history, which may make it difficult to evaluate our business and predict our future performance; We have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability; We will need to raise additional capital to fund our operations and improve our Integrated Drug Creation platform.
If we are unable to raise additional capital on terms acceptable to us or at all, we may not be able to compete successfully, which would harm our business, operations, and financial condition; Biologic drug development is inherently uncertain, and it is possible that our technology may not succeed in discovering appropriate molecules or producing cell lines.
We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements.
Moreover, we operate in a competitive and rapidly changing environment.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →